Genetic disruption of Pdcd-1 upstream enhancer boosts T cell function and antitumor responses

Area of Science:

• Immunology
• Molecular Biology
• Cancer Research

Background:

• Programmed cell death 1 (PD-1) is an inhibitory receptor crucial for T cell exhaustion in tumors, which limits the body's natural antitumor immune response.
• Current therapies targeting PD-1 have demonstrated limited efficacy in cancer treatment.
• Understanding the regulatory mechanisms of PD-1 is essential for developing novel immunotherapeutic strategies.

Purpose of the Study:

• To investigate the role of an upstream enhancer (UpEnh) in regulating the expression of the Pdcd-1 gene, which encodes PD-1.
• To assess the impact of UpEnh deletion on PD-1 levels and T cell function within a tumor microenvironment.

Main Methods:

• Utilized a CRISPR-Cas9 gene editing system to create a knockout mouse model with specific deletion of the UpEnh region.
• Analyzed PD-1 expression levels in various T cell subsets (CD8+, CD4+, Treg, γδ T cells) within tumors using flow cytometry.
• Evaluated T cell function and antitumor immunity in the context of UpEnh deletion.

Main Results:

• Deletion of the UpEnh significantly reduced PD-1 expression across multiple T cell populations, including those within the tumor microenvironment.
• Reduced PD-1 levels correlated with enhanced cytotoxic CD8+ T cell and γδ T cell function.
• The UpEnh knockout model exhibited improved antitumor immunity compared to control groups.

Conclusions:

• The identified UpEnh is a critical regulator of PD-1 expression.
• Targeting UpEnh presents a novel therapeutic strategy to enhance T cell-mediated antitumor immunity.
• Modulating PD-1 through its upstream enhancer offers a promising avenue for improving cancer immunotherapy.